Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
ALUMIS INC. reported the year ended December 31, 2025 results: revenue license revenue of $17.4 million and collaboration revenue of $6.7 million, net income Net loss was $243.3 million.
- Period
- the year ended December 31, 2025
- Revenue
- license revenue of $17.4 million and collaboration revenue of $6.7 million
- Net income
- Net loss was $243.3 million
- Result
- reported results
Exact text from the filing
Revenue included license revenue of $17.4 million and collaboration revenue of $6.7 million for the year ended December 31, 2025, related to the collaboration and licensing agreement with Kaken Pharmaceutical Co., Ltd. ● Research and development expenses were $386.0 million for the year ended December 31, 2025, compared to $265.6 million for the year ended December 31, 2024. The increase was primarily driven by contract research and clinical trial costs for the envudeucitinib and other programs, including costs to support acceleration of clinical trial activities for the Phase 3 ONWARD clinical program, as well as increased headcount to support development efforts and severance costs, including stock-based compensation expense, related to the merger with ACELYRIN. The year ended December 31, 2024 included a clinical milestone payment of $23.0 million related to the prior acquisition of FronThera. ● General and administrative expenses were $91.9 million for the year ended December 31, 2
View on SEC.gov